A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom or Nevanac. Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue dosing on the day of surgery. Beginning one hour before surgery 1 drop of study medication will be instilled by operating room staff approximately every 15 minutes for a total of 3 doses. At the designated time a paracentesis will be performed at the start of the cataract procedure and at least 0.15cc of aqueous humor will be collected. The sample will be immediately stored on dry ice and shipped to a laboratory for analysis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Frank A. Bucci, Jr., M.D.
• Collaborator: Allergan
• Treatments: Bromfenac; Dinoprostone; Ketorolac; Ketorolac Tromethamine; Nepafenac

Criteria

Inclusion Criteria:

• Subjects must be 18 years of age or older

• Scheduled for cataract surgery by phacoemulsification

• Subjects must be willing to comply with all study requirements and be willing to give informed consent

Exclusion Criteria:

• Any subject that has a history of uveitis or active iritis

• Subject can have o previous eye surgery with the exception of refractive surgery but not within 6 month

• No ocular use of prostaglandins within 2 weeks of surgery

• Use of oral, injectable or topical ophthalmic steroids, NSAIDs of immunosuppressants within 14 days prior to surgery

• Contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs)

• Active ocular infection